The PMRA has a process, but I think that's what Paul's comments were. We're looking at the methodology that's being applied in the proposed imidacloprid decision because basically a new study has been triggered also looking at aquatic invertebrates in the context of thiamethoxam.
That's why Paul made the comments he did about the areas of focus or of concern for us in terms of the methodology that's been used. That's why we're here and why we have a keen interest in the proposed decision regarding imidacloprid.